CANNABIS POLAND AB ZY-10 - Asset Resilience Ratio
CANNABIS POLAND AB ZY-10 (8TE) has an Asset Resilience Ratio of 57.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CANNABIS POLAND AB ZY-10 (8TE) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how CANNABIS POLAND AB ZY-10's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of CANNABIS POLAND AB ZY-10.
Liquid Assets Composition Over Time
This chart breaks down CANNABIS POLAND AB ZY-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CANNABIS POLAND AB ZY-10 balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.74 Million | 57.87% |
| Total Liquid Assets | €1.74 Million | 57.87% |
Asset Resilience Insights
- Very High Liquidity: CANNABIS POLAND AB ZY-10 maintains exceptional liquid asset reserves at 57.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CANNABIS POLAND AB ZY-10 Industry Peers by Asset Resilience Ratio
Compare CANNABIS POLAND AB ZY-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for CANNABIS POLAND AB ZY-10 (2023–2025)
The table below shows the annual Asset Resilience Ratio data for CANNABIS POLAND AB ZY-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.87% | €1.74 Million ≈ $2.04 Million |
€3.01 Million ≈ $3.52 Million |
-16.04pp |
| 2024-12-31 | 73.90% | €3.09 Million ≈ $3.62 Million |
€4.19 Million ≈ $4.90 Million |
+10.44pp |
| 2023-12-31 | 63.46% | €1.16 Million ≈ $1.36 Million |
€1.84 Million ≈ $2.15 Million |
-- |
About CANNABIS POLAND AB ZY-10
Cannabis Poland S.A. operates in the medical cannabis industry in Poland. The company distributes and sells cannabidiol (CBD) oils and herbs, inhalers, and vaporizers, as well as dietary supplements and cosmetics for humans and animals. It sells its products through HempWish.pl and Vapem.eu online stores. The company also engages in the research and development of CBD-based drugs based on scienti… Read more